Details for New Drug Application (NDA): 204895
✉ Email this page to a colleague
NDA 204895 describes GALANTAMINE HYDROBROMIDE, which is a drug marketed by Aurobindo Pharma, Barr, Impax Labs, Norvium Bioscience, Sun Pharm, Watson Labs, Hikma, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Rx, Dr Reddys Labs Ltd, Heritage Pharma, Mylan, Sandoz, Yabao Pharm, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. It is available from thirteen suppliers. Additional details are available on the GALANTAMINE HYDROBROMIDE profile page.
The generic ingredient in GALANTAMINE HYDROBROMIDE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.
The generic ingredient in GALANTAMINE HYDROBROMIDE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.
Summary for 204895
| Tradename: | GALANTAMINE HYDROBROMIDE |
| Applicant: | Aurobindo Pharma |
| Ingredient: | galantamine hydrobromide |
| Patents: | 0 |
Pharmacology for NDA: 204895
| Mechanism of Action | Cholinesterase Inhibitors |
Medical Subject Heading (MeSH) Categories for 204895
Suppliers and Packaging for NDA: 204895
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GALANTAMINE HYDROBROMIDE | galantamine hydrobromide | CAPSULE, EXTENDED RELEASE;ORAL | 204895 | ANDA | Aurobindo Pharma Limited | 65862-744 | 65862-744-01 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (65862-744-01) |
| GALANTAMINE HYDROBROMIDE | galantamine hydrobromide | CAPSULE, EXTENDED RELEASE;ORAL | 204895 | ANDA | Aurobindo Pharma Limited | 65862-744 | 65862-744-05 | 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (65862-744-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 8MG BASE | ||||
| Approval Date: | Aug 5, 2016 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 16MG BASE | ||||
| Approval Date: | Aug 5, 2016 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | EQ 24MG BASE | ||||
| Approval Date: | Aug 5, 2016 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
